246 related articles for article (PubMed ID: 34737198)
1. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in
Garcia N; Del Pozo V; Yohe ME; Goodwin CM; Shackleford TJ; Wang L; Baxi K; Chen Y; Rogojina AT; Zimmerman SM; Peer CJ; Figg WD; Ignatius MS; Wood KC; Houghton PJ; Vaseva AV
Mol Cancer Ther; 2022 Jan; 21(1):170-183. PubMed ID: 34737198
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
[TBL] [Abstract][Full Text] [Related]
5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
6. Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
Merchant M; Moffat J; Schaefer G; Chan J; Wang X; Orr C; Cheng J; Hunsaker T; Shao L; Wang SJ; Wagle MC; Lin E; Haverty PM; Shahidi-Latham S; Ngu H; Solon M; Eastham-Anderson J; Koeppen H; Huang SA; Schwarz J; Belvin M; Kirouac D; Junttila MR
PLoS One; 2017; 12(10):e0185862. PubMed ID: 28982154
[TBL] [Abstract][Full Text] [Related]
7. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
8. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
9. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.
Ishii N; Harada N; Joseph EW; Ohara K; Miura T; Sakamoto H; Matsuda Y; Tomii Y; Tachibana-Kondo Y; Iikura H; Aoki T; Shimma N; Arisawa M; Sowa Y; Poulikakos PI; Rosen N; Aoki Y; Sakai T
Cancer Res; 2013 Jul; 73(13):4050-4060. PubMed ID: 23667175
[TBL] [Abstract][Full Text] [Related]
10.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
11. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract][Full Text] [Related]
12. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
13. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
14. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
15. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
16. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
17. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
18. RAF-MEK-ERK pathway in cancer evolution and treatment.
Ullah R; Yin Q; Snell AH; Wan L
Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
[TBL] [Abstract][Full Text] [Related]
19. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
[TBL] [Abstract][Full Text] [Related]
20. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]